MX2013015198A - Vacuna del corona virus canino. - Google Patents

Vacuna del corona virus canino.

Info

Publication number
MX2013015198A
MX2013015198A MX2013015198A MX2013015198A MX2013015198A MX 2013015198 A MX2013015198 A MX 2013015198A MX 2013015198 A MX2013015198 A MX 2013015198A MX 2013015198 A MX2013015198 A MX 2013015198A MX 2013015198 A MX2013015198 A MX 2013015198A
Authority
MX
Mexico
Prior art keywords
canine coronavirus
coronavirus vaccine
vaccine
canine
ccov
Prior art date
Application number
MX2013015198A
Other languages
English (en)
Inventor
Nicola Decaro
Vito Martella
Gabriella Elia
Canio Buonavoglia
Original Assignee
Nicola Decaro
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nicola Decaro filed Critical Nicola Decaro
Publication of MX2013015198A publication Critical patent/MX2013015198A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se describe una nueva cepa del coronavirus canino pantrópico (CC0V), que tiene patogenicidad reducida y es capaz de provocar una respuesta inmune.
MX2013015198A 2011-06-28 2012-06-26 Vacuna del corona virus canino. MX2013015198A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT001182A ITMI20111182A1 (it) 2011-06-28 2011-06-28 Vaccino per coronavirus canino
PCT/EP2012/062347 WO2013000905A1 (en) 2011-06-28 2012-06-26 Canine coronavirus vaccine

Publications (1)

Publication Number Publication Date
MX2013015198A true MX2013015198A (es) 2014-08-18

Family

ID=44504072

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013015198A MX2013015198A (es) 2011-06-28 2012-06-26 Vacuna del corona virus canino.

Country Status (10)

Country Link
US (1) US9200259B2 (es)
EP (1) EP2726096A1 (es)
CN (1) CN103687615A (es)
AU (1) AU2012277893A1 (es)
BR (1) BR112013031760A2 (es)
CA (1) CA2839506A1 (es)
HK (1) HK1197189A1 (es)
IT (1) ITMI20111182A1 (es)
MX (1) MX2013015198A (es)
WO (1) WO2013000905A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104906542A (zh) * 2015-06-12 2015-09-16 天农大（天津）生物科技有限公司 一种治疗犬冠状病毒感染的中药组合物及其制备方法
CN109765384B (zh) * 2019-01-29 2022-11-18 北京勤邦生物技术有限公司 一种犬冠状病毒抗体荧光检测试纸条及其制备方法和应用
CN109970851B (zh) * 2019-04-01 2022-12-06 扬州大学 Ccv病毒m蛋白的单抗及其制备方法、免疫胶体金试纸条的制备方法
CN113234654B (zh) * 2021-05-06 2022-05-10 浙江大学 一种重组枯草芽孢杆菌及其应用
CN115304670A (zh) * 2021-05-07 2022-11-08 华南农业大学 一种猫冠状病毒核衣壳蛋白的鼠源单克隆抗体及其编码基因和应用
CN113817054B (zh) * 2021-10-09 2023-09-01 武汉科前生物股份有限公司 一种特异性结合猪轮状病毒vp6蛋白的鼠单克隆抗体5b11及其应用
CN115747231B (zh) * 2022-11-18 2023-08-04 西南民族大学 Ⅰ型猫冠状病毒病毒样颗粒、制备方法及应用
CN115925827B (zh) * 2022-11-30 2023-11-21 扬州大学 一种应用于检测犬冠状病毒抗体的重组m蛋白及其制备方法与应用
CN116854784B (zh) * 2023-09-05 2023-11-17 北京纳百生物科技有限公司 犬冠状病毒n蛋白抗原截短体及其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US5078996A (en) 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
WO1993013302A1 (de) 1991-12-23 1993-07-08 Michael Zoche Motor mit einer vorrichtung zur entölung
CA2135201A1 (en) * 1992-05-08 1993-11-25 Timothy J. Miller Universal coronavirus vaccine
US5571515A (en) 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5565204A (en) 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
US5846547A (en) 1996-01-22 1998-12-08 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
US6355255B1 (en) 1998-12-07 2002-03-12 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
JP4673974B2 (ja) 1998-09-30 2011-04-20 ワイス・ホールディングズ・コーポレイション アジュバントとしての変異コレラホロトキシン
WO2001093905A1 (en) 2000-06-08 2001-12-13 Intercell Biomedizinische Forschungs- Und Entwicklungs Ag Immunostimulatory oligodeoxynucleotides
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
KR100898648B1 (ko) 2001-06-07 2009-05-22 와이어쓰 홀딩스 코포레이션 보조제로서 콜레라 홀로톡신의 돌연변이체 형태
CA2449670A1 (en) 2001-06-07 2002-12-12 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
GB0217434D0 (en) * 2002-07-27 2002-09-04 Royal Vetinary College Biological material
CA2519511A1 (en) 2003-03-17 2004-09-30 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
GB0410220D0 (en) 2004-05-07 2004-06-09 Kirkham Lea Ann Mutant pneumolysin proteins
EP2283859A3 (en) * 2005-10-26 2011-05-04 Canio Buonavoglia Pantropic canine coronavirus

Also Published As

Publication number Publication date
CN103687615A (zh) 2014-03-26
AU2012277893A8 (en) 2014-01-16
BR112013031760A2 (pt) 2016-12-13
WO2013000905A1 (en) 2013-01-03
AU2012277893A1 (en) 2014-01-09
EP2726096A1 (en) 2014-05-07
HK1197189A1 (en) 2015-01-09
US9200259B2 (en) 2015-12-01
US20140205621A1 (en) 2014-07-24
ITMI20111182A1 (it) 2012-12-29
CA2839506A1 (en) 2013-01-03

Similar Documents

Publication Publication Date Title
MX2013015198A (es) Vacuna del corona virus canino.
PH12018501602A1 (en) Subunit immersion vaccines for fish
BR112013010288A2 (pt) método de produção de uma vacina para proteger um animal de biótipo de microrganismo, vacina para proteger um animal de um biótipo de microrganismo, método para proteger um animal e método para determinar se um animal foi vacinado
EA201291154A1 (ru) Выбор дозы синтетических наноносителей с адъювантами
ZA201309386B (en) Vaccine composition comprising an inactivated chikungunya virus strain
EA201300915A1 (ru) Новый европейский штамм prrsv
CA2798214C (en) Vaccine against beta-herpesvirus infection and use thereof
MX349119B (es) Vacuna de virus de dengue inactivado.
CL2012003299A1 (es) Vacuna que comprende uno o mas antigenos, uno o mas oligonucleotidos inmunoestimuladores aislados y colesterol; metodo para inducir una respuesta inmune antigeno específica en un sujeto que necesita de la misma.
TN2015000259A1 (en) Strain of bifidobacterium animalis ssp. animalis
MX2014006630A (es) Vacuna a base toxina clostridium difficile.
WO2013177444A3 (en) Influenza vaccine constructs
MX2016016746A (es) Composiciones de vacuna con adyuvante dual, preparacion y usos.
NZ715459A (en) A hyperbarically-inactivated microorganism, immunogenic compositions comprising same and methods for producing same
WO2013033496A3 (en) Laser adjuvants for enhancing immune response
EP2686011B8 (en) Ipn vaccine
MX2011005281A (es) Vacuna marcadora de salmonella.
CL2012002504A1 (es) Extracto de cafe que comprende al menos 1 miligramo de un ion multivalente por gramo de solidos de cafe; y metodo de produccion.
HK1162598A1 (en) An infectious cloning system of duck enteritis virus vaccine strain, construction method and use thereof
GB2530210A (en) Novel piscirickettsia salmonis isolate
EP2501405A4 (en) COMPOSITION, METHOD, AND USES OF POX VIRUS ELEMENTS IN VACCINATE CONSTRUCTS
BR112015009300A2 (pt) método de produção de uma vacina para proteger um animal de um biotipo de um microrganismo, método de proteção de um animal de um biotipo de um microrganismo e vacina para proteger um animal de um biotipo de um microrganismo.
SG191331A1 (en) Determination of the efficacy of an anti-mycobacterial vaccination
MX370502B (es) Rotavirus humanos modificados y usos para estos.
UA59897U (ru) Способ изготовления вакцины против бешенства животных "рабизин"